Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes

Medical Hypotheses
Sho-Ichi YamagishiKazuo Nakamura

Abstract

Steno-2 Study has previously shown that intensified multifactorial intervention reduces the risk of nonfatal cardiovascular disease in patients with type 2 diabetes. Further, in the recent follow-up study, intensive therapy was found to have sustained beneficial effects on cardiovascular events and death in this population. A similar outcome was reported in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) Research, which revealed that original intensive therapy reduced the risk of cardiovascular events to about 50% of that of conventional treatment in type 1 diabetic patients 11 years after the end of the trial, although glycosylated hemoglobin values in the two groups had almost converged during the follow-up periods. These two clinical studies strongly suggest that so-called 'metabolic memory' causes chronic vascular damage in diabetic patients, that are not easily reversed, even by subsequent, relatively good control of metabolic risk factors. Potential mechanisms for propagating this 'metabolic memory' are the non-enzymatic glycation of proteins. Indeed, the formation and accumulation of advanced glycation end products (AGEs) have been known to progress at an ...Continue Reading

References

Jul 19, 2005·Current Pharmaceutical Design·Sho-ichi Yamagishi, Tsutomu Imaizumi
Apr 14, 2006·Current Pharmaceutical Design·Sho-ichi YamagishiKazuo Nakamura
Sep 28, 2007·Current Pharmaceutical Design·Sho-ichi YamagishiSeiya Okuda
Feb 22, 2008·Current Pharmaceutical Design·Sho-ichi YamagishiTsutomu Imaizumi
May 10, 2008·Cardiovascular Therapeutics·Sho-ichi YamagishiTsutomu Imaizumi

❮ Previous
Next ❯

Citations

Jul 17, 2009·European Journal of Internal Medicine·David M KendallRichard M Bergenstal
Jun 2, 2009·The American Journal of Medicine·David M KendallRichard M Bergenstal
Aug 25, 2016·Journal of Diabetes·Sho-Ichi YamagishiTakanori Matsui
Nov 26, 2010·International Journal of Pediatric Obesity : IJPO : an Official Journal of the International Association for the Study of Obesity·Jardena J PuderSusi Kriemler
Jul 12, 2013·Cardiovascular Therapeutics·Filipa AlmeidaRaquel Seiça

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.